Three Novel Prebiotics Beat Standard Fiber in Lab Tests on IBD Patient Gut Bacteria

Standard fiber supplements like oligofructose have been the go-to benchmark for prebiotic research, but a new in vitro study published in Food Research suggests three lesser-known carbohydrates may do a better job of reshaping the gut bacteria of people with inflammatory bowel disease. The findings are preliminary, but they point toward a more targeted approach to prebiotic therapy for a condition that affects an estimated 2.4 to 3.1 million Americans and costs the U.S. healthcare system roughly $8.5 billion annually.

Sugar beet, pine, and lemon-derived prebiotics tested against IBD microbiota

The study by Martínez-Gómez and colleagues evaluated three novel carbohydrate mixtures: sugar beet pectooligosaccharides (SBPOS), pine-derived galactoglucomannooligosaccharides (GGMOS), and lemon-derived pectooligosaccharides (LPOS). Each was compared against oligofructose, a well-characterized prebiotic used as a positive control. Faecal samples came from six adults aged 18 to 38, three with ulcerative colitis (UC) and three with Crohn's disease (CD), all in remission or mild relapse at the time of donation.

The baseline microbiota of these donors, though largely recovered from active disease, still showed signs of dysbiosis consistent with IBD remission. Beneficial short-chain fatty acid (SCFA) producers like Faecalibacterium (10 to 15% relative abundance), Blautia (5 to 10%), and Prevotella (7 to 10%) were well represented. Classic probiotic genera like Bifidobacterium and Lactobacillus, by contrast, were barely detectable. CD donors tended to carry higher Firmicutes levels; UC donors had higher Bacteroidota.

When left without any carbohydrate source, the microbial communities deteriorated sharply, with Proteobacteria, a marker of gut dysbiosis and inflammation, blooming more dramatically than is typically seen in healthy donor experiments. That contrast made the carbohydrate supplementation effects stand out clearly.

SBPOS fermentation outperformed oligofructose on SCFA output and selectivity

SBPOS was the most efficiently consumed substrate across both disease types: 75.82% carbohydrate consumption in CD samples and 63.58% in UC samples, both surpassing the oligofructose control. More importantly, SBPOS drove acetate production to 32.96 mM in CD experiments, while oligofructose prompted pronounced lactate accumulation, reaching 60.27 mM in UC, a pattern associated with less favorable fermentation dynamics.

All three novel prebiotics achieved SCFA-to-gas ratios of 3 to 6, compared to roughly 1 for oligofructose. Less gas production relative to beneficial acids is a meaningful practical advantage for IBD patients, who often experience significant bloating and abdominal discomfort. SBPOS selectively enriched Bifidobacterium and Blautia, while oligofructose primarily boosted Lactobacillus. Differential abundance analysis using LEfSe confirmed these distinct microbial fingerprints for each substrate condition.

LPOS produced a different kind of result: fermentation of the lemon-derived prebiotic significantly increased hesperetin bioavailability, with the polyphenol comprising roughly 70% of the final polyphenolic fraction. That secondary effect, transforming a dietary compound into a more bioavailable form, adds a layer of potential benefit that pure fiber supplementation does not offer.

How the team ran the fermentation experiment

Fermentations were run as in vitro static batch cultures under anaerobic conditions at 37 degrees Celsius for 48 hours, using pooled faecal inoculum from the six IBD donors. Samples were collected at 0, 24, and 48 hours. The researchers measured carbohydrate consumption by HPLC, organic acid and SCFA output by HPLC and HPLC-MS/MS, gas production from headspace analysis, and microbial community shifts by 16S rRNA sequencing. Statistical comparisons used non-parametric tests including Kruskal-Wallis and Dunn post hoc corrections, with differential abundance assessed through ANCOM-BC, LEfSe, and Random Forest approaches.

This in vitro fecal fermentation design is a well-established method for screening prebiotic candidates before committing to costly clinical trials, but it has recognized constraints. A key one here: fermentation conditions in closed batch cultures can drift toward a state resembling disease flare rather than remission, meaning some results may overstate fermentation intensity relative to what would occur in a living gut.

Limitations point to a cautious reading of the results

The authors are explicit about the exploratory nature of this work. Only two technical replicates per group were run, and the faecal inoculum was pooled across donors rather than analyzed individually. Pooling reduces noise from inter-individual variation, a real strength when sample sizes are small, but it also erases donor-specific responses that could be clinically meaningful. Research on in vitro gut model methodology consistently highlights this tradeoff: pooled inocula improve reproducibility at the cost of personalized insight.

One particularly interesting gap: butyrate, a SCFA with well-documented anti-inflammatory properties, was not detected in any condition despite the presence of known lactate-to-butyrate converting bacteria. The authors suggest this may reflect delayed cross-feeding that a 48-hour window simply does not capture. The long-term effects of prebiotic supplementation on IBD microbiota remain unclear more broadly, and the inflammatory environment of active IBD can suppress or redirect microbial responses in ways that static in vitro models cannot fully replicate.

The study also notes a tentative site-specificity hypothesis: SBPOS, which ferments quickly, may be better suited to the proximal colon where CD inflammation often concentrates, while the more slowly fermented GGMOS and LPOS could be better matched to the distal colon inflammation typical of UC. That framing is speculative at this stage but offers a rational basis for designing future experiments.

What needs to happen before these prebiotics reach patients

The immediate next step is moving from pooled batch cultures to individual donor fermentations, ideally with a broader range of IBD patients at different disease stages. Clinical prebiotic research in IBD has repeatedly demonstrated that what works in controlled lab conditions does not reliably translate to human trials without careful dose-finding and patient stratification. The disease itself, with its measurable toll on mental health as well as physical function, creates strong motivation to push these candidates forward carefully rather than quickly.

For now, SBPOS stands out as the most promising of the three, with the strongest fermentation efficiency, the most favorable SCFA profile, and the most selective enrichment of beneficial genera. Whether that performance survives the complexity of a living human gut remains the central question this early-stage research cannot yet answer.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• In vitro study only — results from lab fermentation vessels cannot be assumed to translate directly to outcomes in living patients.
• Extremely small sample: fecal inoculum pooled from just six IBD donors (three UC, three CD), making donor-specific or population-level conclusions unreliable.
• Butyrate — a key anti-inflammatory short-chain fatty acid — was not detected despite the presence of bacteria known to produce it, suggesting the model may not fully replicate in vivo gut conditions.
• Funding source was not disclosed by the authors.

In vitro static batch fermentation study using pooled fecal inoculum from six IBD patients (three UC, three CD). Provides mechanistic specificity on named microbial taxa and SCFA outputs but cannot establish causation or clinical efficacy. Results have not been replicated in vivo or in independent laboratory settings.

References

1. Sergio Martínez-Gómez, Joana Sousa, Ana Cordeiro, et al. (2026). A comparative evaluation of new prebiotic candidates. Part 2: In vitro assays using faecal inoculum from IBD patients. Food Research International. https://doi.org/10.1016/j.foodres.2026.119754
2. IBD Facts and Stats – CDC. cdc.gov. https://www.cdc.gov/ibd/data-statistics.html
3. Hokyung Song, Dabin Jeon, Tatsuya Unno (2022). Evaluation of Prebiotics through an In Vitro Gastrointestinal Digestion and Fecal Fermentation Experiment: Further Idea on the Implementation of Machine Learning Technique. Foods. https://doi.org/10.3390/foods11162490
4. Julia Isenring, Lea Bircher, Annelies Geirnaert, Christophe Lacroix (2023). In vitro human gut microbiota fermentation models: opportunities, challenges, and pitfalls. Microbiome Research Reports. https://doi.org/10.20517/mrr.2022.15
5. Cinara Regina A. V. Monteiro, Eduarda G. Bogea, Carmem D. L. Campos, et al. (2026). Prebiotics and Gut Health: Mechanisms, Clinical Evidence, and Future Directions. Nutrients. https://doi.org/10.3390/nu18030372
6. Amin Ariaee, Sabrina Koentgen, Hannah R Wardill, et al. (2024). Prebiotic selection influencing inflammatory bowel disease treatment outcomes: a review of the preclinical and clinical evidence. eGastroenterology. https://doi.org/10.1136/egastro-2023-100055
7. Inflammatory Bowel Disease (IBD) Basics – CDC. cdc.gov. https://www.cdc.gov/ibd/basics.html